GlassScriptPhysician profile
Brooks Bryson Gerlinger
NPI 1366449621
$3,385.50
in general payments reported to CMS, 2019-2025
22 companies · $712 in 2025
The $712 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $339 · 2021: $563 · 2022: $477 · 2023: $405 · 2024: $651 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,768.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $789.15 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $640.32 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.28 | 2019-2025 | Jardiance |
| Amgen INC. | $313.35 | 2019-2025 | Repatha |
| Amarin Pharma, INC. | $182.29 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $175.29 | 2022-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $154.29 | 2021-2025 | |
| Pfizer INC. | $139.03 | 2021-2025 | |
| Bardy Diagnostics, INC. | $135.00 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $134.28 | 2020-2025 | Wainua |
| Kestra Medical Technology Services, INC. | $87.22 | 2025 | Assure Wcd |
| Boston Scientific Corporation | $63.92 | 2020-2021 | |
| Edwards Lifesciences Corporation | $42.65 | 2022 | |
| Novo Nordisk INC | $33.82 | 2021-2023 | Ozempic |
| Lexicon Pharmaceuticals, INC. | $27.94 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $25.37 | 2022 | |
| Atricure, INC. | $22.76 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.41 | 2019-2020 | |
| Daiichi Sankyo INC. | $18.39 | 2024 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $16.53 | 2019 | |
| Inspire Medical Systems, INC. | $13.50 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $11.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooks Gerlinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.